Based upon these preliminary data, the authors inferred that NPM1 mutations alone could not be adequate to explain progression of MDS to AML, requiring further genetic lesions, such as FLT3 gene mutations [62]. This evidence concerns the gene FLT3 and acute myeloid leukemia.